Technology area
Cell therapy
512 funded awards, $319.1M total, FY2023-FY2025.
Where the money sat, by Institute / Center
IC funding decisions are set by portfolio priorities, NOFO scope, and program-officer judgment. These are funded records, not predictions of future funding.
| IC | Name | Records | Median award |
|---|---|---|---|
| CA (NCI) | National Cancer Institute | 122 | $657,754 |
| AI (NIAID) | National Institute of Allergy and Infectious Diseases | 59 | $306,500 |
| DK (NIDDK) | National Institute of Diabetes and Digestive and Kidney Diseases | 53 | $370,020 |
| GM (NIGMS) | National Institute of General Medical Sciences | 53 | $350,000 |
| HL (NHLBI) | National Heart Lung and Blood Institute | 52 | $396,570 |
| AG (NIA) | National Institute on Aging | 38 | $500,000 |
| NS (NINDS) | National Institute of Neurological Disorders and Stroke | 35 | $499,766 |
| TR (NCATS) | National Center for Advancing Translational Sciences | 25 | $350,000 |
| AR (NIAMS) | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 22 | $310,121 |
| MH (NIMH) | National Institute of Mental Health | 19 | $793,383 |
| ES (NIEHS) | National Institute of Environmental Health Sciences | 8 | $700,679 |
| DA (NIDA) | National Institute on Drug Abuse | 5 | $399,997 |
| HD (NICHD) | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 5 | $541,602 |
| EY (NEI) | National Eye Institute | 4 | $331,301 |
| OD | NIH Office of the Director | 4 | $924,586 |
| EB (NIBIB) | National Institute of Biomedical Imaging and Bioengineering | 3 | $996,469 |
| AA (NIAAA) | National Institute on Alcohol Abuse and Alcoholism | 2 | $442,529 |
| HG (NHGRI) | National Human Genome Research Institute | 2 | $350,192 |
| DE (NIDCR) | National Institute of Dental and Craniofacial Research | 1 | $306,868 |
FOA / NOFO routes
Opportunity number prefixes: PA = Parent Announcement (broad, omnibus, multiple ICs), PAR = Parent with Special Review, PAS = Parent with set-aside funds, RFA = Request for Applications (targeted, single-IC, fixed budget). Status unknown means the pipeline has not verified whether the FOA is currently posting awards; the SBIR omnibus has been in reauthorization gap during this window. See the glossary for full definitions.
| Opportunity | Status | Records |
|---|---|---|
| PA-23-230 | unknown | 99 |
| PA-22-176 | unknown | 96 |
| PA-24-245 | unknown | 45 |
| PA-21-259 | unknown | 44 |
| PA-22-178 | unknown | 32 |
| PA-23-232 | unknown | 27 |
| PA-24-247 | unknown | 24 |
| PA-21-262 | unknown | 10 |
| PAS-22-197 | unknown | 10 |
| PA-20-260 | unknown | 10 |
| PA-20-265 | unknown | 9 |
| PA-23-231 | unknown | 8 |
| PA-20-047 | unknown | 7 |
| PAS-22-196 | unknown | 7 |
| PA-21-345 | unknown | 7 |
| PAS-19-316 | unknown | 6 |
| PA-19-272 | unknown | 5 |
| PA-22-177 | unknown | 5 |
| PA-24-246 | unknown | 5 |
| PA-20-272 | unknown | 5 |
| PAR-22-073 | unknown | 5 |
| PA-18-574 | unknown | 4 |
| PA-21-260 | unknown | 2 |
| RFA-DA-19-019 | unknown | 2 |
| RFA-ES-23-008 | unknown | 2 |
| PA-18-573 | unknown | 2 |
| PAR-24-131 | expired | 2 |
| RFA-AG-24-042 | unknown | 2 |
| PA-25-212 | unknown | 2 |
| RFA-CA-22-017 | unknown | 2 |
| PA-19-271 | unknown | 2 |
| PAR-21-225 | unknown | 2 |
| PAR-21-114 | unknown | 2 |
| RFA-DK-21-012 | unknown | 2 |
| RFA-CA-22-025 | unknown | 1 |
| RFA-AA-24-001 | unknown | 1 |
| RFA-MD-24-006 | unknown | 1 |
| RFA-DA-25-053 | unknown | 1 |
| RFA-CA-24-023 | unknown | 1 |
| PA-24-248 | unknown | 1 |
| RFA-DA-25-050 | unknown | 1 |
| RFA-MD-23-003 | unknown | 1 |
| PAR-20-098 | unknown | 1 |
| RFA-NS-20-011 | unknown | 1 |
| PAS-19-317 | unknown | 1 |
| PA-21-261 | unknown | 1 |
| RFA-DK-21-021 | unknown | 1 |
| RFA-ES-22-006 | unknown | 1 |
| PA-21-071 | unknown | 1 |
| RFA-NS-23-006 | unknown | 1 |
| PAR-23-032 | unknown | 1 |
| PA-21-268 | unknown | 1 |
Comparable funded projects
| ApplID | FY | IC | Title | Organization | Amount |
|---|---|---|---|---|---|
| 10598447 | 2025 | CA | Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia | FANNIN PARTNERS, LLC | $999,997 |
| 10907583 | 2025 | CA | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | TWINSTRAND BIOSCIENCES, INC. | $1,985,831 |
| 10983353 | 2025 | TR | A cross-species preclinical platform to enhance the translation of new medicines | CURI BIO INC | $1,149,771 |
| 10997391 | 2025 | AG | A physiologically relevant pre-clinical drug screening platform for Alzheimer's Disease and Traumatic Brain Injury with integrated stretchable microelectrodes | BMSEED, LLC | $779,587 |
| 11001285 | 2025 | AR | Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD | MYOGENICA INC. | $1,266,814 |
| 11001572 | 2025 | MH | A parallelized imaging platform for accurate and efficient long-term assessment of brain organoid development | RAMONA OPTICS, INC. | $475,002 |
| 11031367 | 2025 | DA | Fast-track: Scalable digital delivery of evidence-based training for addiction professionals to maximize treatment admission and retention rates of opioid use disorder in affected families. | WE THE VILLAGE, INC. | $792,422 |
| 11032898 | 2025 | AI | A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed | MARPAM PHARMA, LLC | $979,050 |
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
- Tag 'cell_therapy' is a Cada controlled-vocabulary tag; see methodology for definitions.
Pattern read
Cell therapy is heavily oncology-weighted: NCI accounts for 122 records, with NIAID (59) and NIDDK (53) trailing. NIAID picks up cell-therapy work for immune disorders and select infectious indications; NIDDK reflects diabetes-related beta-cell and regenerative work. Total: 512 records / $319M. Median award is $487K, middling among therapeutic tags. STTR (R41) is unusually well-represented at 77 records, which fits cell therapy's heavy academic-origin pattern; many of these are still co-developed with university labs. Concentration is moderate (6.2%) -- a discernible cluster of repeat awardees but most companies show up once or twice. The tag includes CAR-T, NK-cell, regulatory T-cell, stem-cell-based, and gene-modified-cell approaches.
Fit indicators
Watchouts